Herb Greenberg is the editor of Herb Greenberg's Reality Check, a subscription newsletter designed to help investors better manage risk. He writes a daily blog for TheStreet's main free website and contributes to its Real Money's "Columnist Conversation" column as well as being a regular contributor for CNBC.
Greenberg has been a financial journalist for more than 30 years, working most recently as a senior stocks commentator on CNBC's Business Day programming and on CNBC.com. He was also co-president of Greenberg Meritz Research & Analytics. He is a former weekend investor columnist for The Wall Street Journal and a former senior columnist for MartketWatch.
Prior to joining MarketWatch, Greenberg was senior columnist for TheStreet.com. He previously spent 10 years as the "Business Insider" columnist for the San Francisco Chronicle and nearly seven years as Fortune magazine's monthly "Against the Grain" columnist.
He also was the New York financial correspondent for the Chicago Tribune and a financial reporter in its Chicago newsroom. Greenberg has held various positions at other media outlets including Crain's Chicago Business and the St. Paul Pioneer Press.
Greenberg holds a bachelor's degree in journalism from the University of Miami.
Follow Herb Greenberg on Twitter
As for-profit college scrutiny increases, executive compensation at these companies may be worth a look.
This update on Strayer Education's disagreement with the way the Education Department calculates its student loan repayment rates: The department is telling us, at CNBC, that having heard Strayer's spacer complaints, it intends to do intential analysis.
On Friday, the Department of Education issued a report on the rate of loan repayments by college students. This is important because if the rates are too low students at those schools might not qualify for government loans,, without which some of these companies would have a hard time making a go of it.
Given events in recent days, you can’t help but wonder whether Best Buy can avoid cutting its full-year guidance, which would not appear to bode well for its stock.
Just because a company loses more than half its value, as has been the case with Amedisys in recent months, doesn't mean it can't go lower.